OTCPK:UCBB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

US-China Biomedical Technology

Executive Summary

US-China Biomedical Technology, Inc. operates as an early stage biomedical technology and services company. More Details


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has US-China Biomedical Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: UCBB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-79.1%

UCBB

0.2%

US Healthcare

-1.5%

US Market


1 Year Return

-0.7%

UCBB

17.8%

US Healthcare

12.9%

US Market

Return vs Industry: UCBB underperformed the US Healthcare industry which returned 17.8% over the past year.

Return vs Market: UCBB underperformed the US Market which returned 12.9% over the past year.


Shareholder returns

UCBBIndustryMarket
7 Day-79.1%0.2%-1.5%
30 Day-77.7%-3.0%-1.8%
90 Day-46.5%1.0%6.6%
1 Year-0.7%-0.7%19.4%17.8%15.4%12.9%
3 Year-98.8%-98.8%30.3%24.5%39.6%30.2%
5 Year-99.4%-99.4%59.8%48.4%93.4%71.7%

Price Volatility Vs. Market

How volatile is US-China Biomedical Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is US-China Biomedical Technology undervalued compared to its fair value and its price relative to the market?

5.69x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate UCBB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate UCBB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: UCBB is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: UCBB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate UCBB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: UCBB is overvalued based on its PB Ratio (5.7x) compared to the US Healthcare industry average (2.8x).


Next Steps

Future Growth

How is US-China Biomedical Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as US-China Biomedical Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of UCBB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access US-China Biomedical Technology's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has US-China Biomedical Technology performed over the past 5 years?

22.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: UCBB is currently unprofitable.

Growing Profit Margin: UCBB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if UCBB's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare UCBB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UCBB is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).


Return on Equity

High ROE: UCBB has a negative Return on Equity (-599.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is US-China Biomedical Technology's financial position?


Financial Position Analysis

Short Term Liabilities: UCBB's short term assets ($155.0K) do not cover its short term liabilities ($254.2K).

Long Term Liabilities: UCBB's short term assets ($155.0K) exceed its long term liabilities ($140.4K).


Debt to Equity History and Analysis

Debt Level: UCBB is debt free.

Reducing Debt: UCBB currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if UCBB has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if UCBB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is US-China Biomedical Technology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate UCBB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate UCBB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UCBB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UCBB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of UCBB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

21.7yrs

Average management tenure


CEO

Sunny Huang (47 yo)

2.83yrs

Tenure

Mr. Qingxi Huang, also known as Sunny, has been Chief Executive Officer, Chief Financial Officer, President, Secretary and Treasurer of US-China Biomedical Technology, Inc. (formerly known as Cloud Securit ...


Leadership Team

NamePositionTenureCompensationOwnership
Qingxi Huang
Chairman2.83yrsno datano data
Jennifer Johnson
Co-Founder21.67yrsno datano data
Brennan Johnson
Co-Founder21.67yrsno datano data

21.7yrs

Average Tenure

Experienced Management: UCBB's management team is seasoned and experienced (21.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

US-China Biomedical Technology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: US-China Biomedical Technology, Inc.
  • Ticker: UCBB
  • Exchange: OTCPK
  • Founded: 2010
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$531.092k
  • Shares outstanding: 19.82m
  • Website: https://www.ucbb.us

Number of Employees


Location

  • US-China Biomedical Technology, Inc.
  • 2 Park Plaza
  • Suite 400
  • Irvine
  • California
  • 92614
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UCBBOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMay 2012

Biography

US-China Biomedical Technology, Inc. operates as an early stage biomedical technology and services company. The company was formerly known as Cloud Security Corporation and changed its name to US-China Bio ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/22 06:38
End of Day Share Price2020/09/21 00:00
Earnings2019/05/31
Annual Earnings2019/02/28


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.